Dengue Testing Market Outlook:
Dengue Testing Market size was over USD 780.4 million in 2024 and is estimated to reach USD 1.7 billion by the end of 2034, expanding at a CAGR of 7.1% during the forecast timeline, i.e., 2025-2034. In 2025, the industry size of dengue testing is estimated at USD 832.1 million.
The continuously growing demand, with 5.3 million confirmed cases reported in 2024 across tropical and subtropical regions, is fueling robust growth in the market, as per the World Health Organization (WHO). Similarly, in 2024, the Centers for Disease Control and Prevention (CDC) recorded a 40.2% surge in cases due to climate-driven mosquito habitat expansion. In response, governments in high-risk countries, such as India, Brazil, and Indonesia, are expanding diagnostic programs and spreading awareness about the importance of early intervention. As evidence, a study from the Agency for Healthcare Research and Quality (AHRQ) revealed that early testing can offer a 32.4% reduction in hospitalizations and save $850.3 million for the U.S. healthcare system over two years.
The cost increase of raw materials and logistics is notably translating to an economic burden on payers of the market. This can be displayed through a 4.3% year-over-year (YoY) increase in the producer price index (PPI) for diagnostic components in 2023, according to the World Bank. This inflation is further absorbed by the consumer price index (CPI), showcasing a 5.9% rise, for testing services in 2024. Such financial changes ultimately impact outbreak zones with the heightening demand. To minimize such disparity, governments and insurance providers are trying to maintain testing accessibility in high-burden regions. Moreover, these efforts are helping companies mitigate global supply chain disruption and raw material shortage.
